Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Safety

FDA delays rule on generic drug labels

by Glenn Hess, special to C&EN
May 30, 2016 | A version of this story appeared in Volume 94, Issue 22

FDA is putting off until 2017 a decision on whether to allow generic drug makers to independently update safety warnings on product labels. The rule was widely expected to be finalized this spring. Currently, brand-name drug makers have an obligation to update a label whenever they discover new information about a drug, and generic manufacturers are required to follow suit. In 2011, the U.S. Supreme Court ruled that generic drug makers could not be sued for failing to warn patients about the risks of their products because the companies do not control the content of the warning labels. FDA says its proposal would “create parity” between brand-name and generic drug makers because it would expose companies in both industries to lawsuits if they fail to properly warn of a drug’s risks. The Generic Pharmaceutical Association has objected, arguing the rule change would create confusion because drugs that are equivalent could have different warning labels.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.